Therapeutic challenges in the era of antibiotic resistance

International Journal of Antimicrobial Agents

Volumn 32, Issue SUPPL. 4, 2008, Pages

  Lee, Christopher ^a  

^a HOSPITAL SUNGAI BULOH   (Malaysia)

Author keywords

Antibiotic resistance; Empirical therapy; Treatment options

Indexed keywords

CARBAPENEM DERIVATIVE; CEFTRIAXONE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DORIPENEM; ERTAPENEM; GATIFLOXACIN; LINEZOLID; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TELITHROMYCIN; TIGECYCLINE;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ARTICLE; ENTEROCOCCAL INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DAPTOMYCIN; DRUG RESISTANCE, MICROBIAL; HUMANS; MINOCYCLINE; OXAZOLIDINONES;

EID: 58149147607     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(09)70002-0     Document Type: Article

References (23)

1. Infectious Disease Society of America. Bad bugs, no drugs: as antibiotic discovery stagnates, a public health crisis brews (2004), Infectious Disease Society of America, Alexandria, VA. http://www.idsociety.org/WorkArea/showcontent.aspx?id=5554 [accessed 21 July 2008].
2. Norrby S.R., Nord C.E., and Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis 5 (2005) 115-119
3. Talbot G.H., Bradley J., Edwards Jr. J.E., Gilbert D., Scheld M., Bartlett J.G., et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42 (2006) 657-668
4. Finch R., and Hunter P.A. Antibiotic resistance - action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005. J Antimicrob Chemother 58 Suppl 1 (2006) i3-i22
5. Fridkin S.K., Hageman J.C., Morrison M., Sanza L.T., Como-Sabetti K., Jernigan J.A., et al. Meticillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 352 (2005) 1436-1444
6. Enserink M. Infectious diseases. Resistant staph finds new niches. Science 299 (2003) 1639-1641
7. Tong S.Y., McDonald M.I., Holt D.C., and Currie B.J. Global implications of the emergence of community-associated meticillin-resistant Staphylococcus aureus in indigenous populations. Clin Infect Dis 46 (2008) 1871-1878
8. Gorwitz R.J. Understanding the success of meticillin-resistant Staphylococcus aureus strains causing epidemic disease in the community. J Infect Dis 197 (2008) 179-182
9. Johnson A.P., Sheppard C.L., Harnett S.J., Birtles A., Harrison T.G., Brenwald N.P., et al. Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England. J Antimicrob Chemother 52 (2003) 953-960
10. Livermore D.M., James D., Reacher M., Graham C., Nichols T., Stephens P., et al. Trends in fluoroquinolone (ciprofloxacin) resistance in Enterobacteriaceae from bacteremias, England and Wales, 1990-1999. Emerg Infect Dis 8 (2002) 473-478
11. Muller A., Lopez-Lozano J.M., Bertrand X., and Talon D. Relationship between ceftriaxone use and resistance to third-generation cephalosporins among clinical strains of Enterobacter cloacae. J Antimicrob Chemother 54 (2004) 173-177
12. Kumamoto Y., Tsukamoto T., Matsukawa M., Kunishima Y., Hirose T., Shigeta S., et al. Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). III. Secular changes in susceptibility [in Japanese]. Jpn J Antibiot 59 (2006) 217-315
13. Lee K., Lim C.H., Cho J.H., Lee W.G., Uh Y., Kim H.J., et al. High prevalence of ceftazidime-resistant Klebsiella pneumoniae and increase of imipenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. in Korea: a KONSAR program in 2004. Yonsei Med J 47 (2006) 634-645
14. Rhomberg P.R., Deshpande L.M., Kirby J.T., and Jones R.N. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006). Diagn Microbiol Infect Dis 59 (2007) 425-432
15. Naas T., Fortineau N., Snanoudj R., Spicq C., Durrbach A., and Nordmann P. First nosocomial outbreak of vancomycin-resistant Enterococcus faecium expressing a VanD-like phenotype associated with a vanA genotype. J Clin Microbiol 43 (2005) 3642-3649
16. Song J.H., Ko K.S., Suh J.Y., Oh W.S., Kang C.I., Chung D.R., et al. Clinical implications of vancomycin-resistant Enterococcus faecium (VRE) with VanD phenotype and vanA genotype. J Antimicrob Chemother 61 (2008) 838-844
17. Ikonomidis A., Tokatlidou D., Kristo I., Sofianou D., Tsakris A., Mantzana P., et al. Outbreaks in distinct regions due to a single Klebsiella pneumoniae clone carrying a bla VIM-1 metallo-β-lactamase gene. J Clin Microbiol 43 (2005) 5344-5347
18. Pitout J.D., Nordmann P., Laupland K.B., and Poirel L. Emergence of Enterobac-teriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 56 (2005) 52-59
19. Jimenez-Mejias M.E., Pachon J., Becerril B., Palomino-Nicás J., Rodríguez-Cobacho A., and Revuelta M. Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam. Clin Infect Dis 24 (1997) 932-935
20. Navon-Venezia S., Leavitt A., and Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 59 (2007) 772-774
21. Khardori N. Antibiotics-past, present, and future. Med Clin North Am 90 (2006) 1049-1076
22. Revenge of the killer microbes: Are we losing the war against infectious diseases?. Time 144 11 (1994) cover.
23. Finch R. Innovation - drugs and diagnostics. J Antimicrob Chemother 60 Suppl 1 (2007) i79-i82